Colorado decision support / safety-first review
A practical way to assess ibogaine program claims before treating travel, cost, or marketing as evidence of safety. This is independent information, not medical or legal advice.
For broader context before using this checklist, start with Peregrine Silt’s Colorado-focused decision guide and keep your questions specific, documented, and unhurried.
01 / Before any commitment
A credible conversation about risk starts before travel. It should not rely on a short intake, a verbal assurance, or a generic claim that a program is “medical.” Ibogaine has been associated with potentially serious cardiac risk, including changes in cardiac rhythm; the FDA’s discussion of QT-related rhythm concerns illustrates why medication effects and ECG findings deserve careful attention.
Ask whether prior records, diagnoses, cardiac history, substance use, current medications, supplements, and recent changes are reviewed before acceptance. A program that does not request meaningful information cannot demonstrate an individualized screening process.
Ask whether an ECG is required, who reads it, when it is repeated, and how QTc findings are handled. Do not accept a number alone as a clearance decision; QTc interpretation depends on the clinical picture and qualified judgment.
Ask for a written approach to medication and substance interactions, including who coordinates changes with a person’s existing prescribers. The NCBI overview of drug interactions is a useful reminder that combinations and timing can alter effects in ways marketing cannot resolve.
“Safer” is not a promise. It is a question of whether risk is identified, documented, explained, and supported by a credible response plan.
02 / Onsite safeguards
Continuous observation is not the same thing as medical monitoring. Ask directly whether cardiac telemetry is used, whether abnormal findings can be recognized in real time, and what happens if a participant needs escalation. A basic understanding of electrocardiography can help frame why an ECG and ongoing rhythm monitoring answer different questions.
Ask whether the setting is disclosed in advance and whether its limitations are explained plainly.
Ask what is monitored continuously, who watches it, and how concerns are documented.
Ask about resuscitation equipment, emergency protocols, transfer arrangements, and decision authority.
Ask which qualified medical personnel are onsite, what each role covers, and when coverage changes.
03 / People and documentation
Ask who conducts the assessment, who reviews clinical information, who is responsible during the session, and who can make an emergency decision. Roles should be understandable without relying on vague titles or promotional language. For a wider view of how to evaluate claims and constraints, the way Peregrine Silt frames practical decision support may help keep questions focused on evidence rather than branding.
Independent resources such as ibogaine policy and research updates can add context, but they do not replace direct answers from a program or advice from a clinician who knows the person’s history.
04 / Red-flag review
These questions are not a certification system. They are a way to notice whether a program provides specifics that can be reviewed, whether it makes room for uncertainty, and whether it respects a person’s right to pause.
Cost can create pressure to overlook missing safeguards. Use a comparison of treatment-cost questions only as one part of a decision, alongside evidence about screening and monitoring rather than as a substitute for them.
05 / After the immediate setting
A program should be able to describe what support it offers after the immediate experience, what it does not provide, and when local care is needed. It should not suggest that a brief program replaces continuing mental health care, substance-use treatment, or primary medical care.
Ask about the timing, format, and limits of follow-up; whether a participant receives written records; and what referrals or crisis resources are offered if concerns arise after returning home.
When travel is involved, ask who coordinates handoff to local care. Resources that compare possible treatment locations can clarify practical differences, but travel complexity should not be minimized.
Claims about benefits should be treated as claims, not guarantees. Explore questions about purported ibogaine benefits with attention to uncertainty, individual differences, and the difference between anecdote and evidence.
06 / Common decision points
Medication and substance review is a basic screening question because interactions, withdrawal timing, and cardiac effects can materially change risk. A program should be able to explain what records it needs and what questions remain for a local clinician.
Consent should plainly cover uncertainty, known risks, alternatives, monitoring limits, follow-up expectations, and legal context. A person should have time to read it and ask questions without pressure.
Ibogaine remains a controlled substance under U.S. federal law. Review the DEA’s explanation of drug scheduling, and consult local clinicians and qualified legal counsel where appropriate before acting on plans involving possession, travel, or cross-border arrangements.
Location does not answer the safety questions. If travel is being considered, use location-planning questions for ibogaine treatment to examine jurisdiction, continuity of care, records, emergency access, and the realities of returning home.
For questions about supportive practices after a program, the discussion of therapy-related expectations may help distinguish ongoing support from promises that cannot be verified in advance.
Pause before committing
Bring this checklist to a local clinician where appropriate. Keep copies of records and consent materials. A decision involving medical and legal uncertainty deserves time, independent questions, and the option to step back.
Review considerations for choosing abroad